
Detector Dogs: Agriculture's Best Friend
MISSION, Kan., June 16, 2025 /PRNewswire/ — (Family Features) They may be cute, fluffy and friendly, but some dogs also have an important job: protecting America's food supply.
By deploying specially trained beagles, Labrador retrievers and Jack Russell terriers, the U.S. Department of Agriculture's (USDA) Animal Plant Health Inspection Services' (APHIS) Detector Dog Program puts elite canines to work on the front lines at international airports, mail facilities and border crossings throughout the nation. These furry sleuths maneuver between passengers and luggage to search, locate and respond to the presence of banned fruits, plants and meats that may harbor damaging insects and diseases that threaten the country's agricultural production and natural resources.
The program was started in 1984 and soon grew in demand. By 2009, APHIS opened a 17-acre National Detector Dog Training Center near the Atlanta International Airport. At the center, dogs and their handlers go through an 8-10-week training program to learn how to inspect passenger luggage and handbags for agricultural goods such as fruits, vegetables, beef and pork.
Detector dogs patrol ports of entry, borders and airports to keep harmful pests, like invasive fruit flies, out of the country. For example, labrador retrievers and their handlers protect the nation's fruit by patrolling citrus orchards along the Texas–Mexico border in search of infested or diseased crops.
Safeguarding U.S. agriculture and natural resources is part of the program's mission, but APHIS' Detector Dog Program also partners with countries like Canada and Taiwan to supply guidance, training and testing of canine detection. There are even detector dog teams on the job at cargo airports throughout countries in the Pacific, tasked with identifying invasive species and stopping them from reaching Hawaii. The work these dogs and their handlers do is critical to help stop the spread of invasive plant and animal pests and diseases that could ravage America's agriculture.
A detector dog's career spans 6-8 years before they retire at 9 years old. At retirement age, 90% of dogs are adopted by their handler. In the rare case they are not, the handler will recommend a good home and a successful adoption program ensures all dogs are well placed.
Constantly on the lookout for new pups, APHIS works closely with animal shelters, rescue groups and private individuals to find the right dogs for the job from anywhere in the country. New recruits are 1-3 years old, heartworm negative, have high food drive and are environmentally and socially friendly. The ideal candidate is often that high-energy, hard-to-handle pooch who simply needs a job and a purpose.
If you or someone you know would like to help the program grow its squad of super sniffers, email usdacanineadoptions@usda.gov, call (887) 797-3899 or learn more at aphis.usda.gov/aphis/ourfocus/planthealth/ppq-program-overview/nddtc.
Content courtesy of USDA
Michael Frenchmfrench@familyfeatures.com 1-888-824-3337editors.familyfeatures.com
About Family Features Editorial SyndicateA leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at Culinary.net and eLivingToday.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
4 days ago
- Malaysian Reserve
Peanuts Provide Much-needed Protein for GLP-1 Users
Plus, Three Macronutrients in Peanuts Support Body's Natural GLP-1 Response ALBANY, Ga., June 24, 2025 /PRNewswire/ — Today, an increasing number of Americans are taking GLP-1 medications to combat obesity and type 2 diabetes, which are serious health issues. GLP-1s deliver a number of benefits, including reduced appetite, better weight management and improved blood sugar control. However, there can be significant side effects. 'While GLP-1s can promote weight loss, some research shows that up to 60% of the loss can come from lean mass rather than fat,1″ says Samara Sterling, Ph.D., a nutrition scientist and director of research for The Peanut Institute. 'That's why it's vitally important for users to closely monitor their diet to ensure they're eating enough nutrient-rich foods, including those that are healthy sources of protein. Specifically, protein supports tissues in the body, including muscles, bones, cartilage, skin and blood.' That's where peanut products come in. Peanuts and peanut butter can be a key dietary element for GLP-1 users because peanuts contain significant amounts of protein, fiber and healthy fats. Research suggests those three macronutrients can help support the body's natural GLP-1 response.2 In addition, the Cleveland Clinic recently shared that 'eating peanuts may help you maintain a healthy weight and avoid having obesity.3,4″ Peanut Protein PlussesAccording to the United States Department of Agriculture Nutrient Database, a single serving of peanuts (about 1 ounce) packs seven grams of protein, which is more than any other nut5,6. In addition, peanuts are a plant-based protein, and a long-term study found that swapping one daily serving of animal protein for plant protein (like peanuts or peanut butter) decreases the risk of developing type 2 diabetes.7 Another benefit of peanuts is that they are packed with 19 vitamins and minerals, including niacin, vitamin E and magnesium. In fact, peanuts provide 25% of the recommended daily allowance (RDA) of niacin, which aids skin and nerve function and the digestive system and protects against Alzheimer's disease and cognitive decline.8 On top of that, peanuts are an excellent source of vitamin E, an antioxidant that supports immune function and is a 'hard-to-get' nutrient for men and women.9 In addition, per serving, peanuts deliver 12% of the RDA of magnesium, which has been found to aid blood sugar, heart rhythm, the immune system, blood pressure and even bones. Magnesium intake is also associated with reduced inflammation and a reduced risk of metabolic syndrome and type 2 diabetes.10, 11 Fulfilling Fiber RequirementsUnfortunately, most Americans only get about 15 grams of dietary fiber per day—substantially less than the recommended amount of 22-34 grams.12 For those taking a GLP-1, fiber is important because constipation can be an uncomfortable side effect. Gradually increasing fiber intake can be helpful during and after GLP-1 therapy.2 Another positive is that fiber helps increase satiety (the feeling of being 'full' and satisfied after a meal) and supports overall digestive health. Fortunately, peanuts are a good source of fiber, providing nearly three grams per serving, which is similar to a 1/2 cup of cooked quinoa or a 1/4 cup of dates.13 Peanut skins also contain dietary fiber, along with other micronutrients that may help to support healthy gut bacteria, strengthen the immune system, regulate blood sugar and reduce inflammation.14,15, 16, 17 Peanut skins deliver other benefits. Roasted peanuts with skins have a higher antioxidant capacity than blueberries.18 Antioxidants have been shown to help prevent oxidative damage in the body that can lead to heart disease and cancer.19 Heart-healthy FatsGLP-1 medications work in part by slowing down how quickly the stomach empties. Eating high-fat meals (like fried foods or fast food) can slow it down further—leading to uncomfortable side effects like nausea or bloating. Sticking with a moderate amount of healthy fats, like those in peanuts, olive oil and avocados, is less likely to upset digestion.2 More than 80% of the fats in peanuts are from heart-healthy unsaturated fats. About 50% of that is monounsaturated fat, the same type found in avocado and olive oil, while 30% is polyunsaturated fat, which is important for the heart. Because of this unique combination, the 2020-2025 Dietary Guidelines for Americans named nuts like peanuts as a key recommendation.20 Studies show that replacing saturated fats with monounsaturated and polyunsaturated fats can offer substantial benefits, including: A reduction in LDL or 'bad' cholesterol that can lead to blocked arteries.21 A reduction in the risk of a heart attack or stroke. 21, 22, 23 A reduction in the risk of dying from cardiovascular disease.21 For those who are taking GLP-1s and anyone who'd like to incorporate more protein, vitamins and minerals into their diet, The Peanut Institute has created a collection of tasty recipes for meals and snacks, including Chickpea and Peanut Falafel, Roasted Carrot and Peanut Soup and Spicy Peanut Hummus. Check out the high protein, high fiber and weight management recipes at or follow on Facebook, Twitter, Instagram, LinkedIn and Pinterest. Based in Albany, Ga., The Peanut Institute is a non-profit organization supporting nutrition research and developing educational programs to encourage healthful lifestyles that include peanuts and peanut products. The Peanut Institute pursues its mission through research programs, educational initiatives and the promotion of healthful lifestyles to consumers of all ages. As an independent forum, The Peanut Institute is uniquely positioned to work with all segments of the food industry, the research community, academia, consumer organizations and governmental institutions. Sources 1. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27. PMID: 38937282.2. Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sannidhi D, Stanford FC, Callahan EA. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025 May 30. doi: 10.1002/oby.24336. Epub ahead of print. PMID: 40445127.3. Petersen KS, Murphy J, Whitbread J, Clifton PM, Keogh JB. The Effect of a Peanut-Enriched Weight Loss Diet Compared to a Low-Fat Weight Loss Diet on Body Weight, Blood Pressure, and Glycemic Control: A Randomized Controlled Trial. Nutrients. 2022 Jul 21;14(14):2986. doi: 10.3390/nu14142986. PMID: 35889947; PMCID: PMC9318508.5. 'USDA Food Composition Databases.' U.S. Department of Agriculture. Search for 'legumes and legume products, 100 g,' March 12, 2018. 6. 'USDA Food Composition Databases.' U.S. Department of Agriculture. Search for 'nut and seed products, 100 g,' March 12, 2018. 'Dietary Protein Intake and Risk of Type 2 Diabetes in US Men and Women.' V.S. Malik et al. American Journal of Epidemiology. 2016, vol. 183, no. 8, pp. 715-28. 8. Morris MC, Evans DA, Bienias JL, Scherr PA, Tangney CC, Hebert LE, Bennett DA, Wilson RS, Aggarwal N. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1093-9. PubMed PMID: 15258207; PubMed Central PMCID: PMC1739176.9. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th Edition. December 2020.10. Larsson SC, Orsini N, Wolk A. Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. Am J Clin Nutr. 2012 Feb;95(2):362-6. doi: 10.3945/ajcn.111.022376. Epub 2011 Dec 28. PubMed PMID: 22205313.11. Larsson SC, Wolk A. Magnesium intake and risk of type 2 diabetes: a meta-analysis. J Intern Med. 2007 Aug;262(2):208-14. Review. PubMed PMID: 17645588.12. 'Dietary Guidelines for Americans 2015-2020, 8th Edition.' U.S. Department of Agriculture, December 2015. US Department of Agriculture, Agricultural Research Service, Nutrient Data Laboratory USDA National Nutrient Database for Standard Reference, Release 28. [(accessed on 13 February 2019)]; Version Current: September 2015, Slightly Revised May 2016. Available online: Nguyen SM, Tran TDC, Tran TM, Wang C, Wu J, Cai Q, Ye F, Shu X-O. Influence of Peanut Consumption on the Gut Microbiome: A Randomized Clinical Trial. Nutrients. 2024; 16(19):3313. Arya SS, Salve AR, Chauhan S. Peanuts as functional food: a review. J Food Sci Technol. 2016 Jan;53(1):31-41. doi: 10.1007/s13197-015-2007-9. Epub 2015 Sep 19. Review. PubMed PMID: 26787930; PubMed Central PMCID: PMC4711439. 16. Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr. 2013 Mar;97(3):505-16. doi: 10.3945/ajcn.112.042457. Epub 2013 Jan 30. Review. PubMed PMID: 23364002. 17. Xu M, Lv C, Wang H, Lu Q, Ye M, Zhu X, Liu R. Peanut skin extract ameliorates high-fat diet-induced atherosclerosis by regulating lipid metabolism, inflammation reaction and gut microbiota in ApoE-/- mice. Food Res Int. 2022 Apr;154:111014. doi: 10.1016/ Epub 2022 Feb 16. PMID: 35337573. 18. Craft BD, et al. Antioxidant Properties of Extracts Obtained from Raw, Dry-Roasted, and Oil-Roasted US Peanuts of Commercial Importance. Plant Foods Hum Nutr. 2010. Sep;65(3):309-10.19. Falasca M, Casari I, Maffucci T. Cancer chemoprevention with nuts. J Natl Cancer Inst. 2014; 106:dju238. 10.1093/jnci/dju23820. U.S. Department of Agriculture, & U.S. Department of Health and Human Services. (2020). Dietary Guidelines for Americans, 2020–2025 (9th ed., p. ix). U.S. Government. 'Dietary Fats and Cardiovascular Disease: A Presidential Advisory from the American Heart Association.' F.M. Sacks et al. Circulation. 2017, vol. 136, no. 3, pp. E1-e24. 22. 'Monounsaturated Fat.' American Heart Association. 'Polyunsaturated Fat.' American Heart Association.


Malaysian Reserve
4 days ago
- Malaysian Reserve
Mark Hensley joins RBL LLC as a senior adviser
HOUSTON, June 24, 2025 /PRNewswire/ — RBL LLC, a pioneering biotech venture creation studio designed to rapidly build companies based on lifesaving medical technologies, today announced the addition of Mark Hensley as a senior adviser. Hensley will leverage his proven experience in biotech venture creation, corporate strategy and business development to accelerate the development and commercialization of breakthrough life sciences technologies at the Houston-based venture creation studio. With more than 15 years of experience in the biotechnology industry, Hensley brings a wealth of knowledge in company formation, venture financing, mergers and acquisitions and strategic partnerships. He has a proven track record of successfully identifying high-potential biotech opportunities and scaling new ventures across a variety of therapeutic areas, including transplant, immunology and rare diseases. 'Following our October launch, we expect Mark's impressive track record of leading large business transactions in the biotech industry, coupled with his deep expertise in strategic partnerships, to play an instrumental role in advancing our mission,' said Paul Wotton, CEO and managing partner of RBL LLC. 'As we continue launching cutting-edge biomedical innovations, we look forward to working with Mark's strategic guidance to drive the development of breakthrough therapies from the lab bench to the clinic.' 'Joining RBL LLC as it prepares for the launch of multiple promising clinical-stage biotech companies is a great opportunity,' Hensley said. 'I look forward to working alongside the talented team at RBL LLC to help identify and steer innovative Houston-based biotech ventures to success while fostering the strategic partnerships necessary to accelerate the development of therapies that will have a lasting impact on patients worldwide.' Hensley currently serves as chief operating officer at Heron Therapeutics, a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Prior to this role, he served as CEO of Veloxis Pharmaceuticals, where he led a major buy-side acquisition, expanding the company's global footprint in nephrology. As chief commercial officer at Veloxis, he played a pivotal role in executing a billion-dollar sell-side transaction, demonstrating his strategic vision and ability to drive substantial growth in the biotechnology sector. Hensley holds a Bachelor of Science in biology with a minor in chemistry from the University of North Texas, and his expertise spans a wide range of disciplines within the biotechnology and life sciences industries. About RBL LLC:RBL LLC is a pioneering biotech venture creation studio based in Houston that is dedicated to accelerating the development of breakthrough medical technologies and therapies through company formation. RBL provides entrepreneurs, researchers and innovators with infrastructure, financial support and strategic guidance as well as access to laboratory space and shared resources in the Texas Medical Center Helix Park. For more information, please visit Media Contact: Russo PartnersDavid Schull or Liz Phillips(347)


Malaysian Reserve
4 days ago
- Malaysian Reserve
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ — Genprex, Inc. ('Genprex' or the 'Company') (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago. 'We are proud of the research presented at the ADA conference, which demonstrates that alpha cells in animal models of T1D have undergone transdifferentiation to beta-like cells after being transduced with GPX-002. In addition, the beta-like cells were still providing improved control of glucose levels after three months,' said Ryan Confer, President and Chief Executive Officer at Genprex. 'We are very excited to continue evaluating GPX-002 as we further optimize how to control anti-viral immunity and move toward human clinical trials.' The oral presentation details for the Genprex-supported abstract at the ADA 85th Scientific Sessions: Title: Recombinant AAV-mediated Gene Therapy For The Treatment Of Streptozotocin-Induced Diabetes in Non-Human PrimatesType: Oral PresentationTrack: Immunology/Beta-Cell ReplacementCategory: Exploring Alternative Strategies to Stem Cell-Derived Beta Cells and Insights from Autologous Islet TransplantationPresentation Date: Monday, June 23, 2025Presentation Time: 1:30 p.m. CTPresenter: Hannah Rinehardt, MD, University of Pittsburgh Medical Center The oral presentation discussed GPX-002, the diabetes gene therapy, which uses infusion of recombinant adeno-associated virus (rAAV) retrograde into the pancreatic duct to deliver the Pdx1 and MafA genes. The gene therapy converts alpha cells into beta-like cells that secrete insulin physiologically, reversing diabetes in mouse models, where immunosuppression was not necessary. Researchers evaluated the immune response to direct infusion of rAAV into the pancreatic duct of non-human primates (NHPs) with streptozotocin-induced diabetes and evaluated how to best manage immune responses against the virus capsid proteins. Diabetes was induced with streptozotocin (STZ) in cynomolgus macaques, a type of NHP. NHPs received retrograde intraductal infusion of rAAV via laparotomy for precise delivery to the pancreas. rAAV capsids were chosen based on tropism for endocrine cells, and pre-existing neutralizing antibody titers (NAbs) were negative. Expression of viral proteins occurs for a limited period of time after rAAV infection, since the infection doesn't produce new AAV virus. One-month post-infusion, NHPs showed improved glucose tolerance and reduced insulin requirements. In the following months, using steroid-sparing regimens, increases in pancreatic B and T lymphocyte populations were noted on single cell RNA sequencing. Temporary immunosuppression (IS), using a combination of rituximab, rapamycin, and steroids for a 3-month course is largely effective at preventing anti-viral immunity. However, discontinuation of IS at 3 months post-infusion led to an immune response afterwards, indicating that IS in NHPs may need to be continued longer, and six months of IS in NHPs is now being evaluated. When colocalization of insulin and glucagon is quantified, there was significantly elevated colocalization in treated islets compared to untreated diabetic and non-diabetic controls. This suggests that GPX-002 can lead to transdifferentiation of alpha cells into a new population of beta-like cells that make insulin but still retain the capacity to produce glucagon. In conclusion, the novel rAAV gene therapy research demonstrated that infusion of rAAV directly into the pancreatic duct of NHPs leads to transdifferentiation of alpha cells to beta-like cells with restoration of glucose homeostasis. IS, including steroids, is necessary for a number of months to prevent anti-viral immunity in NHPs. Researchers are continuing preclinical studies of GPX-002 therapy in NHP models of both Type 1 and Type 2 diabetes to generate additional data, and current studies are evaluating viral efficacy after six months of IS. About GPX-002GPX-002, which has been exclusively licensed from the University of Pittsburgh, is currently being developed using the same construct for the treatment of both Type 1 diabetes (T1D) and Type 2 diabetes (T2D). The same general novel approach is used in each of T1D and T2D whereby an adeno-associated virus (AAV) vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. In T1D, GPX-002 is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In vivo, preclinical studies show that GPX-002 restored normal blood glucose levels for an extended period of time in T1D mouse models. In T2D, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells. About Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn. Cautionary Language Concerning Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under 'Item 1A – Risk Factors' in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals, including but not limited to, the Company's beliefs about the anticipated effects of GPX-002 and its potential as a therapeutic approach; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc.(877) 774-GNPX (4679) GNPX Investor Relationsinvestors@ GNPX Media ContactKalyn Dabbsmedia@